EUROCHIP - EUROpean Cancer Health Indicators Project A fight against disequalities in managing cancer HMP HMP: Health Monitoring Programme Andrea Micheli.

Slides:



Advertisements
Similar presentations
The Place of Multiple Sclerosis in the European Union Policy – the example of EMSPs MS Barometer 2008 Christoph Thalheim Secretary General, European MS.
Advertisements

High Resolution Italian studies Pamela Minicozzi Descriptive Studies and Health Planning Unit, Department of Preventive and Predictive Medicine, Fondazione.
Current status of EHES Kari Kuulasmaa EHES meeting Luxembourg, 2 March 2011.
Capacity Building for Public Health and Health Promotion in Central and Eastern Europe Caroline Costongs Programme Manager EuroHealthNet
EUROCHIP-1&2 Health Indicators for Monitoring Cancer in Europe Health Monitoring Program (HMP) EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
EUROCHIP-3: WP-4 Publications Paolo Baili Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
The importance of cancer data & registries to understand the cancer burden (EUROCHIP) ECPC Cancer Summit 2010, October 2010 Dr. Andrea Micheli Director.
High Resolution data for rare cancers Annalisa Trama Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy ) WORKSHOP FOR A EUROPEAN HIGH RESOLUTION.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
EUROCHIP-2 the action Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN.
EUROCHIP Health Indicators for Monitoring Cancer in Europe Health Monitoring Program (HMP) A Micheli.
National Cancer Registry Luxembourg EUROCHIP-3 Meeting Ispra, 27 th February 2012 Olivier Collignon, PhD, Sophie Couffignal, MD, CRP-Santé.
EIPA Headquarters Maastricht (NL) Antenna Barcelona (ES) Antenna Barcelona (ES) Antenna Luxembourg (LU) Antenna Milan (IT) Ann Stoffels © EIPA 2006 EIPA.
Erasmus Thematic Network Sanne Hirs, Project coordinator Faculty of Law, Utrecht University.
Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.
Cancer inequalities in Europe Kielce, Polish conference on cancer, 13/15 June 2011 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit.
ISARE : Health indicators in the regions of Europe André Ochoa for Isare team ISARE : Health indicators in the regions of Europe André Ochoa for Isare.
Health & Consumer Protection Directorate General EU Public Health Programme and action on rare diseases John F Ryan Head of Unit European Commission.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
EUROCHIP-2 European Public Health Action on Cervical Cancer Screening GRELL Palma de Majorca Public Health Program EUROPEAN COMMISSION: HEALTH &
1 EUROPA DONNA – The European Breast Cancer Coalition Susan Knox, Executive Director KEEPING BREAST CANCER ON THE EUROPEAN HEALTH AGENDA.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news EUROCHIP-2 THE ACTION Project & news Public.
Kathrin Strasser-Weippl 1 st Medical Department Wilhelminen Hospital, Vienna Cancer Care in Europe.
DISCUSSION. EUROCHIP-2 ACTION PLAN COUNTRY 1COUNTRY 2COUNTRY 3 COUNTRY 30 ACTION1ACTION1 ACTION2ACTION2 ACTION3ACTION3 ACTION3ACTION3 ACTION4ACTION4 ACTION4ACTION4.
Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Information network on rare cancers INFORMATION NETWORK ON RARE CANCERS (RARECARENet) Kick-off meeting - Friday, July Gemma Gatta Fondazione IRCCS,
EUROCHIP-2 EUROCHIP-2 - The Action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Presenter: U. Rothe/ U. Manuwald Institution: 3 rd WP7 meeting Istituto Superiore di Sanità, Roma July, 2-3, 2015 Questionnaire on Prevention and Management.
European Union against cancer The EUROCHIP project 1st International Cancer Control Congress Vancouver, October 2005 Public Health Program EUROPEAN.
CAF Resource Centre at EIPA Open Days Patrick Staes Senior Expert European Institute of Public Administration THE COMMON ASSESSMENT FRAMEWORK.
Strength in Numbers Mar The Delian League  Countries do not want to be dominated by other countries.  But there are many advantages to be gained.
European Topic Centre on Biological Diversity EIONET consultation on SEBI process Sophie Condé ETC/BD, Katarzyna.
EUROCHIP-Italia in EUROCHIP-2 Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
© Enterprise Europe Network South West 2009 The Eurostars Programme Kenny Legg R&D Funding for the Environmental Sector – 29 June 2010 European Commission.
Risk Management Standards and Guidelines
E-notes European NGOs Observatory on Trafficking, Exploitation and Slavery Brussels, 20 October
Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Table 1. Numbers and rates of TB cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
European Innovation Scoreboard European Commission Enterprise and Industry DG EPG DGs meeting, May 2008.
Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based.
NSO data collections of subjective well-being
Table 1. Reported confirmed hepatitis A cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
DISTRIBUTION AUTOMATIC - GENERATION
Lifelong Learning Programme 2007 – 2013
Table 1. Reported, confirmed campylobacteriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes,
Table 1. Number and rate of reported confirmed syphilis cases per 100 000 population by country and year, EU/EEA, 2010–2014 Country
Table 1. Reported confirmed brucellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
The European Parliament – voice of the people
The European Parliament – voice of the people
HEDIC Health expenditures by diseases and conditions
EU: First- & Second-Generation Immigrants
Table 1. Table 1. Reported confirmed salmonellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y.
Table 1. Reported confirmed VTEC infection cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N.
Niek Klazinga, Trnava, Thursday
Table 1. Reported confirmed cholera cases, EU/EEA, 2010–2014
STEERING COMMITTEE MEETING
Table 1. Reported confirmed botulism cases: number and rate per population, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
Chapter 8: International Groupings History of the EU: Timeline
JOINT ACTION HEALTH EQUITY EUROPE About JAHEE…
Table 1. Reported confirmed listeriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
Includes data from the Welsh Cancer Intelligence and Surveillance Unit
Table 1. Reported confirmed yersiniosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
Prodcom Statistics in Focus
Presentation transcript:

EUROCHIP - EUROpean Cancer Health Indicators Project A fight against disequalities in managing cancer HMP HMP: Health Monitoring Programme Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2, Riccardo Capocaccia 3, Jan Willem Coebergh 4, Arduino Verdecchia 3, Franco Berrino 1, Eugenio Mugno 1, Camilla Amati 1, Michel Coleman 5 1 Unit of Epidemiology – Istituto Nazionale per la Cura e lo Studio dei Tumori – Milan (I) – 2 Granada Cancer Registry – Escuela Andaluza de Salud Publica – Granada (E), 3 Laboratory of Epidemiology and Biostatistics – Istituto Superiore di Sanità – Rome (I), 4 Comprehnsive Cancer Centre South Eindhoven Cancer Registry – Eindhoven (NL), 5 Cancer and Public Health Unit – London School of Hygiene & Tropical Medicine – London (UK) THE PROJECT Produce a list of health indicators describing cancer in Europe in order for: a) helping the development of European Health Information System b) reducing inequalities in cancer control c) promoting action in the fight against cancer 130 INTELLECTUAL WORK INVOLVING 130 CANCER SPECIALISTS OF EU MEMBERS, CANCER NETWORKS, INSTITUTES AND ORGANISATIONS METHODS EUROCHIP AIMS BACKGROUND TERTILES: I: Estonia, Poland, Slovenia, Slovakia, and Spain; II: UK, Finland, Netherland, Sweden, Italy, and Austria; III: Iceland, Denmark, France, Germany, and Switzerland CANCER SITES TO BE CONSIDERED FOR THE LIST 1)All cancers combined without non melanoma skin cancers 2)Cancers of: lung, breast, colorectal, prostate, stomach,head and neck, larynx, oropharynx, melanoma, kaposi, mesothelioma, testis, haematopoietic malignancies, childhood tumors, cervix Each indicator was discussed by groups of experts of different expertise in prevention, cancer registration, screening, treatment and health economy, who described it by its general presentation, operational definition, meaning, possible use, caveat, modalities of classification, possible source, standardisation and validity. EUROCHIP provided a list of cancer malignancies taken as proxy of different phases of cancer surveillance : LIST OF INDICATORS AND THEIR AVAILABILITY: COMPARISON BETWEEN EUROPE AND US CONCLUSIONS AND FUTURE EUROCHIP achieved to produce a list of indicators and to gather guidelines and for the European health information system on cancer. Final goal of EUROCHIP was to find information able to describe differences and also to promote action that would reduce inequalities in managing cancer. This last is the core of the ongoing EUROCHIP-2 project. It will be really useful to compare European data with American ones. Today this is possible for some European countries and for traditional epidemiological measures, but it is important to highlight that many indicators proposed by EUROCHIP are already available in US. To reduce inequalities across Europe, some countries have to prioritise action on prevention, others on care, others on surveillance. However, it is vital for each countries’ success in the fight against cancer, that the trans-national European nature of the study is maintained at all levels of data collection, data analysis, problem evaluation, and action. EUROCHIP-2 will add value to each countries actions by stimulating data comparison (also with US data) and providing a unified International/European imprimatur to cancer action. EUROCHIP-2 will try to:  SET UP DATA COLLECTION  ANALYSE THE BEHAVIOUR OF VARIOUS INDICATORS IN RELATION TO THEIR UTILITY  IDENTIFY DEFICIENCIES IN EUROPEAN HEALTH SYSTEMS  ENCOURAGE ACTIONS TO REDUCE INADEQUANCIES IN CANCER CONTROL A: Availability for large part of Europe; B: US Department of Health and Human Services, Public Health Service, NIH, National Cancer Institute. CANCER PROGRESS REPORT 2001; C: Surveillance Research Program, National Cancer Institute. SEER*Stat software Version ( *: From OECD Health Data 2002